| Autor: |
Le RQ; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Przepiorka D; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Chen H; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Shen YL; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Pulte ED; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Norsworthy K; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Theoret MR; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD., De Claro RA; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD. |
| Abstrakt: |
Abstract: Complete remission with partial hematological recovery (CRh) has been used as an efficacy endpoint in clinical trials of nonmyelosuppressive drugs for acute myeloid leukemia (AML). We conducted a pooled analysis to characterize the clinical outcomes for patients with AML who achieved CRh after treatment with ivosidenib, olutasidenib, enasidenib, or gilteritinib monotherapy in clinical trials used to support marketing applications. The study cohort included 841 adult patients treated at the recommended drug dosage; 64.6% were red blood cell or platelet transfusion dependent at study baseline. Correlations between disease response and outcomes were assessed by logistic regression modeling for categorical variables and by Cox proportional hazards modeling for time-to-event variables. Patients with CRh had a higher proportion with transfusion independence (TI) for at least 56 days (TI-56; 92.3% vs 22.3%; P < .0001) or TI for at least 112 days (TI-112; 63.5% vs 8.7%; P < .0001), a reduced risk over time for severe infection (hazard ratio [HR], 0.43; P = .0007) or severe bleeding (HR, 0.17; P = .01), and a longer overall survival (OS; HR, 0.31; P < .0001) than patients with no response. The effects were consistent across drugs. In comparison with patients with CR, the effect sizes for CRh were similar for TI-56 and for risk over time of infection or bleeding but less for TI-112 and OS. CRh is associated with clinical benefits consistent with clinically meaningful palliative effects for the treatment of AML with nonmyelosuppressive drugs, although less robustly than for CR. |
